Abstract
Gastric cancer ranks as the sixth most prevalent cancer worldwide. In recent research within the realm of gastric cancer treatment, the identification and application of immune-related genetic features have emerged as groundbreaking advancements. The study by Ma et al, which developed a prognostic model based on 10 genes, categorizes patients into high and low-risk groups to predict their responsiveness to immune checkpoint inhibitor therapy. This research underscores the potential of immune-related genes as biomarkers for personalized treatment, offering insights into tumor mutation burden and immune phenotype scores. We advocate for further validation, understanding of biological mechanisms, and integration of diverse datasets to enhance the model's predictive accuracy and clinical application, marking a significant step towards personalized and precise treatment for gastric cancer.